U.S. pharmaceutical stocks declined, with BioNTech (BNTX.US) dropping 11%, marking its largest intraday loss since March 10, after the company announced the termination of its Phase II colorectal cancer clinical trial. Moderna (MRNA.US) fell 5%, and Merck (MRK.US) dropped 1.3%.

U.S. pharmaceutical stocks declined, with BioNTech (BNTX.US) dropping 11%, marking its largest intraday loss since March 10, after the company announced the termination of its Phase II colorectal cancer clinical trial. Moderna (MRNA.US) fell 5%, and Merck (MRK.US) dropped 1.3%.

智通财经2026/08/28 13:42

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

U.S. pharmaceutical stocks declined, with BioNTech (BNTX.US) falling 11%, marking its largest intraday drop since March 10, after the company announced the termination of its phase 2 clinical trial for colorectal cancer. Moderna (MRNA.US) dropped 5%, and Merck (MRK.US) slipped 1.3%.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

U.S. pharmaceutical stocks declined, with BioNTech (BNTX.US) dropping 11%, marking its largest intraday loss since March 10, after the company announced the termination of its Phase II colorectal cancer clinical trial. Moderna (MRNA.US) fell 5%, and Merck (MRK.US) dropped 1.3%.

You may also like

Crypto prices